Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

Stephen Hoge was one of three kickers vying for the starting job at Kansas University. Hoge announced on Monday, August 18, that he has left the team. Stephen Hoge was one of three kickers vying ...

FDA flags Guillain-Barré risks for GSK, Pfizer RSV shots, but just one will need safety trial Moderna's president, Stephen Hoge, M.D., expanded on the news, pointing out in a call with investors ...

Stephen Hoge, President: Regarding Norovirus, GBS occurs in the background population, and we paused activities to prioritize patient safety. The FDA placed us on hold while reviewing our ...

President Stephen Hoge noted progress in pivotal studies for respiratory and non-respiratory vaccines. He shared updates on approvals filed for next-gen COVID, RSV, and flu-COVID combination ...

On today's call are Stéphane Bancel, Chief Executive Officer; Jamey Mock, Chief Financial Officer; and Stephen Hoge, President. Before we begin, please note that this conference call will include ...

“The virus is changing its stripes, and we will change to make sure we can beat the virus where it’s going,” Stephen Hoge, the president of Moderna, tells The Washington Post. A study from Moderna ...

Dr Stephen Hodge Dr Stephen Hodge is Chief Technology Officer at Versarien plc, an advanced engineering materials group. The company creates innovative engineering solutions for its clients in a ...